Skip to main content
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2003 May;111(5):757–774. doi: 10.1289/ehp.5947

Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rationale for and avenues toward a green pharmacy.

Christian G Daughton 1
PMCID: PMC1241487  PMID: 12727606

Abstract

Since the 1980s, the occurrence of pharmaceuticals and personal care products (PPCPs) as trace environmental pollutants, originating primarily from consumer use and actions rather than manufacturer effluents, continues to become more firmly established. Although PPCPs typically have been identified in surface and ground waters, some are also undoubtedly associated with solid phases such as suspended particulates, sediments, and sewage sludges, despite their relatively high affinity for water. Often amenable to degradation, their continual introduction to waste-receiving waters results from their widespread, continuous, combined use by individuals and domestic animals, giving PPCPs a "pseudo-persistence" in the environment. Little is known about the environmental or human health hazards that might be posed by chronic, subtherapeutic levels of these bioactive substances or their transformation products. The continually growing, worldwide importance of freshwater resources, however, underscores the need for ensuring that any aggregate or cumulative impacts on (or from) water supplies are minimized. Despite the paucity of effects data from long-term, simultaneous exposure at low doses to multiple xenobiotics (particularly non-target-organism exposure to PPCPs), a wide range of proactive actions could be implemented to reduce or minimize the introduction of PPCPs to the environment. Most of these actions fall under what could be envisioned as a holistic stewardship program--overseen by the health care industry and consumers alike. Significantly, such a stewardship program would benefit not just the environment; additional, collateral benefits could automatically accrue, including reducing consumers' medication expenses and improving patient health and consumer safety. In this article, the first of a two-part mini-monograph describing the "green pharmacy," I focus initially on the background behind the imperative for an ecologically oriented stewardship program for PPCPs. I then present a broad spectrum of possible source control/reduction actions, controlled largely by the health care industry, that could minimize the disposition of PPCPs to the environment. This two-part mini-monograph attempts to capture cohesively for the first time the wide spectrum of actions available for minimizing the release of PPCPs to the environment. A major objective is to generate an active dialog or debate across the many disciplines that must become actively involved to design and implement a successful approach to life-cycle stewardship of PPCPs.

Full Text

The Full Text of this article is available as a PDF (469.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alper Joe. Drug delivery. Breaching the membrane. Science. 2002 May 3;296(5569):838–839. doi: 10.1126/science.296.5569.838. [DOI] [PubMed] [Google Scholar]
  2. Arroll B., Kenealy T., Kerse N. Do delayed prescriptions reduce the use of antibiotics for the common cold? A single-blind controlled trial. J Fam Pract. 2002 Apr;51(4):324–328. [PubMed] [Google Scholar]
  3. Crain S. M., Shen K. F. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res. 2001 Jan 5;888(1):75–82. doi: 10.1016/s0006-8993(00)03010-9. [DOI] [PubMed] [Google Scholar]
  4. Daughton C. G., Ternes T. A. Pharmaceuticals and personal care products in the environment: agents of subtle change? Environ Health Perspect. 1999 Dec;107 (Suppl 6):907–938. doi: 10.1289/ehp.99107s6907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Evans Arthur T., Husain Shahid, Durairaj Lakshmi, Sadowski Laura S., Charles-Damte Marjorie, Wang Yue. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet. 2002 May 11;359(9318):1648–1654. doi: 10.1016/S0140-6736(02)08597-5. [DOI] [PubMed] [Google Scholar]
  6. Fernandez-Lopez S., Kim H. S., Choi E. C., Delgado M., Granja J. R., Khasanov A., Kraehenbuehl K., Long G., Weinberger D. A., Wilcoxen K. M. Antibacterial agents based on the cyclic D,L-alpha-peptide architecture. Nature. 2001 Jul 26;412(6845):452–455. doi: 10.1038/35086601. [DOI] [PubMed] [Google Scholar]
  7. Handley D. A., Tinkelman D., Noonan M., Rollins T. E., Snider M. E., Caron J. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma. 2000 Jun;37(4):319–327. doi: 10.3109/02770900009055455. [DOI] [PubMed] [Google Scholar]
  8. Heberer Thomas. Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicol Lett. 2002 May 10;131(1-2):5–17. doi: 10.1016/s0378-4274(02)00041-3. [DOI] [PubMed] [Google Scholar]
  9. Kolpin Dana W., Furlong Edward T., Meyer Michael T., Thurman E. Michael, Zaugg Steven D., Barber Larry B., Buxton Herbert T. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ Sci Technol. 2002 Mar 15;36(6):1202–1211. doi: 10.1021/es011055j. [DOI] [PubMed] [Google Scholar]
  10. Lazarou J., Pomeranz B. H., Corey P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998 Apr 15;279(15):1200–1205. doi: 10.1001/jama.279.15.1200. [DOI] [PubMed] [Google Scholar]
  11. Lee Sang Bok, Mitchell David T., Trofin Lacramioara, Nevanen Tarja K., Söderlund Hans, Martin Charles R. Antibody-based bio-nanotube membranes for enantiomeric drug separations. Science. 2002 Jun 21;296(5576):2198–2200. doi: 10.1126/science.1071396. [DOI] [PubMed] [Google Scholar]
  12. Lipsitch Marc, Singer Randall S., Levin Bruce R. Antibiotics in agriculture: when is it time to close the barn door? Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5752–5754. doi: 10.1073/pnas.092142499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Magnani M., Rossi L., Fraternale A., Bianchi M., Antonelli A., Crinelli R., Chiarantini L. Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther. 2002 Jun;9(11):749–751. doi: 10.1038/sj.gt.3301758. [DOI] [PubMed] [Google Scholar]
  14. McGovern Susan L., Caselli Emilia, Grigorieff Nikolaus, Shoichet Brian K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem. 2002 Apr 11;45(8):1712–1722. doi: 10.1021/jm010533y. [DOI] [PubMed] [Google Scholar]
  15. Miller Greg. Drug targeting. Breaking down barriers. Science. 2002 Aug 16;297(5584):1116–1118. doi: 10.1126/science.297.5584.1116. [DOI] [PubMed] [Google Scholar]
  16. Munoz-Bellido J. L., Munoz-Criado S., Garcìa-Rodrìguez J. A. Antimicrobial activity of psychotropic drugs: selective serotonin reuptake inhibitors. Int J Antimicrob Agents. 2000 Apr;14(3):177–180. doi: 10.1016/s0924-8579(99)00154-5. [DOI] [PubMed] [Google Scholar]
  17. Nuovo Jim, Melnikow Joy, Chang Denise. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA. 2002 Jun 5;287(21):2813–2814. doi: 10.1001/jama.287.21.2813. [DOI] [PubMed] [Google Scholar]
  18. Phillips K. A., Veenstra D. L., Oren E., Lee J. K., Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001 Nov 14;286(18):2270–2279. doi: 10.1001/jama.286.18.2270. [DOI] [PubMed] [Google Scholar]
  19. Rosenthal Meredith B., Berndt Ernst R., Donohue Julie M., Frank Richard G., Epstein Arnold M. Promotion of prescription drugs to consumers. N Engl J Med. 2002 Feb 14;346(7):498–505. doi: 10.1056/NEJMsa012075. [DOI] [PubMed] [Google Scholar]
  20. Schowanek Diederik, Webb Simon. Exposure simulation for pharmaceuticals in European surface waters with GREAT-ER. Toxicol Lett. 2002 May 10;131(1-2):39–50. doi: 10.1016/s0378-4274(02)00064-4. [DOI] [PubMed] [Google Scholar]
  21. Slovic P. The risk game. J Hazard Mater. 2001 Sep 14;86(1-3):17–24. doi: 10.1016/s0304-3894(01)00248-5. [DOI] [PubMed] [Google Scholar]
  22. Smith David L., Harris Anthony D., Johnson Judith A., Silbergeld Ellen K., Morris J. Glenn., Jr Animal antibiotic use has an early but important impact on the emergence of antibiotic resistance in human commensal bacteria. Proc Natl Acad Sci U S A. 2002 Apr 23;99(9):6434–6439. doi: 10.1073/pnas.082188899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Straub Jürg Oliver. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001. Toxicol Lett. 2002 May 10;131(1-2):137–143. doi: 10.1016/s0378-4274(02)00049-8. [DOI] [PubMed] [Google Scholar]
  24. Thornton J. Beyond risk: an ecological paradigm to prevent global chemical pollution. Int J Occup Environ Health. 2000 Oct-Dec;6(4):318–330. doi: 10.1179/oeh.2000.6.4.318. [DOI] [PubMed] [Google Scholar]
  25. Veber Daniel F., Johnson Stephen R., Cheng Hung-Yuan, Smith Brian R., Ward Keith W., Kopple Kenneth D. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002 Jun 6;45(12):2615–2623. doi: 10.1021/jm020017n. [DOI] [PubMed] [Google Scholar]
  26. Velagaleti Ranga, Burns Philip K., Gill Michael, Prothro James. Impact of current good manufacturing practices and emission regulations and guidances on the discharge of pharmaceutical chemicals into the environment from manufacturing, use, and disposal. Environ Health Perspect. 2002 Mar;110(3):213–220. doi: 10.1289/ehp.02110213. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES